Sage Therapeutics, Inc. (SAGE)
NASDAQ: SAGE · Real-Time Price · USD
8.75
-0.22 (-2.45%)
Jul 22, 2025, 4:00 PM - Market closed
Sage Therapeutics Stock Forecast
Stock Price Forecast
The 17 analysts that cover Sage Therapeutics stock have a consensus rating of "Hold" and an average price target of $9.48, which forecasts a 8.34% increase in the stock price over the next year. The lowest target is $4 and the highest is $26.
Price Target: $9.48 (+8.34%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Sage Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 3 | 3 | 3 | 3 | 2 | 1 |
| Hold | 15 | 15 | 14 | 14 | 15 | 15 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 1 | 1 | 1 | 1 | 0 | 0 |
| Total | 20 | 20 | 19 | 19 | 18 | 17 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Scotiabank | Scotiabank | Buy → Hold Downgrades $12 → $9.2 | Buy → Hold | Downgrades | $12 → $9.2 | +5.14% | Jul 8, 2025 |
| Baird | Baird | Hold Maintains $7 → $9 | Hold | Maintains | $7 → $9 | +2.86% | Jun 20, 2025 |
| Piper Sandler | Piper Sandler | Buy → Hold Downgrades $9 → $8.5 | Buy → Hold | Downgrades | $9 → $8.5 | -2.86% | Jun 17, 2025 |
| Truist Securities | Truist Securities | Hold Maintains $8 → $9 | Hold | Maintains | $8 → $9 | +2.86% | Jun 17, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $12 | Hold | Reiterates | $12 | +37.14% | Jun 17, 2025 |
Financial Forecast
Revenue This Year
83.19M
from 41.24M
Increased by 101.71%
Revenue Next Year
118.38M
from 83.19M
Increased by 42.30%
EPS This Year
-3.67
from -6.59
EPS Next Year
-2.94
from -3.67
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 136.4M | 198.7M | 229.8M | ||
| Avg | 83.2M | 118.4M | 155.4M | ||
| Low | 61.7M | 78.4M | 110.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 230.7% | 138.8% | 94.1% | ||
| Avg | 101.7% | 42.3% | 31.3% | ||
| Low | 49.6% | -5.8% | -6.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.08 | -1.76 | -0.74 | ||
| Avg | -3.67 | -2.94 | -2.00 | ||
| Low | -3.90 | -3.85 | -3.90 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.